  |
The MedWatch September 2013 Safety Labeling Changes posting includes 49 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT.
The "Summary Page" provides a listing of product names and safety labeling sections revised:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm371272.htm
The following drugs had modifications to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS and PRECAUTIONS sections:
Arzerra (ofatumumab)
CombiPatch (estradiol/norethindrone acetate transdermal system)
Potiga (ezogabine)
Rituxan (rituximab)
Tasigna (nilotinib)
Tygacil (tigecycline)
Accupril (quinapril hydrochloride)
Accuretic (quinapril hydrochloride/HCTZ)
Altace (ramipril)
Arixtra (fondaparinux sodium)
Janumet (sitagliptin and metformin HCl)
Plasma-Lyte 148 and Plasma-Lyte A pH 7.4 (Multiple Electrolytes, Type 1, USP)
Septra and Septra DS (Trimethoprim and Sulfamethoxazole)
Suprane (desflurane, USP)
Apidra (insulin glulisine [rDNA origin])
CellCept (mycophenolate mofetil)
Biaxin (clarithromycin tablets, USP)
Biaxin Granules (clarithromycin for oral suspension, USP)
Biaxin XL Filmtabs (clarithromycin extended release tablets)
Gemcitabine Injection
Golytely (PEG 3350 and electrolytes)
Jentadueto (linagliptin and metformin hydrochloride)
Myfortic (mycophenolic acid)
Nulytely (PEG 3350 and electrolytes)
Plavix (clopidogrel bisulfate)
Prograf (tacrolimus)
Prograf (tacrolimus)
Remodulin (treprostinil)
Terazol (terconazole)
Unisom SleepTabs (doxylamine succinate)
Vimpat (lacosamide)
Zometa (zoledronic acid)
Zosyn (piperacillin and tazobactam for injection, USP)
You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
| This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
